Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsNancy Sullivan, Bimal Chakrabarti, Zhi-Yong Yang, Maria Grazia Pau, Jaap Goudsmit, Gary Nabel
Estimating the term…
The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
An isolated nucleic acid molecule having SEQ ID NO:5.
An isolated plasmid DNA comprising a CMV immediate early enhancer promoter, an HTLV-1 R region and the Marburg/Angola GP/h insert of SEQ ID NO:5.
An isolated recombinant virus comprising the Marburg/Angola GP/h insert of SEQ ID NO:5.
An isolated adenovirus comprising the Marburg/Angola GP/h insert of SEQ ID NO:5.
Dependencies are inferred from the claim text.